Matchpoint Therapeutics Stock

Matchpoint Therapeutics is a biotechnology company that integrates chemoproteomics, ML, and covalent chemistry to treat serious illnesses.

Sign up today and learn more about Matchpoint Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Matchpoint Therapeutics Stock

Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines, initially focused on immunology.

Funding History

November 2021$30.0M
October 2022$70.0M

Management

Board Member

Dan Becker

Board Member

Andre Turenne

President and CEO

G. Andre Turenne

Board Member

Jason P. Hafler

Board Member

Bruce Booth

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo